Wed Feb 12, 2014 9:26am EST —
Wed Feb 12, 2014 9:31am EST
Executives and guests of Inovio Pharmaceuticals, Inc. will visit the New York Stock Exchange (NYSE) on Wednesday, Feb 12, 2014.
To mark the occasion, Dr. J. Joseph Kim, President & CEO, Inovio Pharmaceuticals Inc., will ring the NYSE Opening Bell.
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO)
Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.